Business Wire

XPRIZE Announces New $10 Million Competition to Preserve Rainforests Across the Globe

19.11.2019 15:00:00 EET | Business Wire | Press release

Share

Today, XPRIZE, the global leader in designing and operating incentive competitions to solve humanity’s grand challenges, officially launched the $10M Rainforest XPRIZE. Registration is now open for teams interested in participating in the four-year global competition that calls on innovators to create technology capable of identifying and cataloging rainforest biodiversity and develop insights that may lead to a new bioeconomy through standing forests.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005397/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

Rainforests remain undervalued, which has led to their rapid depletion over the past two decades. Having once covered 14% of the earth’s land surface, rainforests now cover a mere 6% of the planet, according to National Geographic. Specifically, the recent acceleration of the Amazon’s deforestation, due in part to illegal logging and mining as well as inefficient agricultural expansion, has added to climate insecurity around the globe. All these factors have elevated the urgency of bringing the importance of preserving these precious ecosystems to the forefront of international discourse. Knowledge of the full biodiversity must be unlocked so that private companies, corporations, governments, individuals, local communities, and indigenous people who have demonstrated a commitment to preserving the rainforests will be empowered to sustain rainforests rather than destroy them.

The Rainforest XPRIZE will reward teams that can develop effective new technology to capture the true biological diversity of rainforests and further layer additional data to show the value of protecting the natural resources within them. The current methods used to identify and catalogue biodiversity, including in situ human-led studies, remote sensing by satellites or radar, or sophisticated spectroscopy, cannot operate to scale and gather the data necessary to understand the full ecosystem wealth of rainforests in sustainable ways. The competition accelerates a new bioeconomy, while also engaging indigenous and local communities, as well as local academic institutions in developing the solution. The Rainforest XPRIZE is a call-to-action to help save rainforests through the development and implementation of transformative, scalable, and affordable technology.

Anousheh Ansari, CEO of XPRIZE, said, “Amid our 25th anniversary as an organization, it is fitting that we add to our legacy by introducing a prize that will challenge the best and brightest to develop transformative technology to incentivize the preservation of rainforests worldwide, not only for our generation, but those to follow.”

“Despite their importance in supporting life on Earth, rainforests are undervalued because we simply do not yet know everything that exists in this ancient ecosystem,” said Executive Director of the Rainforest XPRIZE Jyotika Virmani, Ph.D. “I’m excited to see the innovative technologies that will emerge from this competition and give us a better assessment of the incredible biodiversity. Our goal is for the Rainforest XPRIZE to provide new understanding and reveal the true potential of the standing forest, allowing local communities to lead the way for all of us to live in harmony with these magnificent rainforests.”

The teams of the Rainforest XPRIZE will develop sophisticated technologies to inventory rainforest biodiversity faster, affordably, and in unprecedented detail in challenging harsh environments, delivering insights to support the sustainable use and well-being of the standing forest. Interdisciplinary teams can use emerging technologies such as robotics, remote sensing, data analysis, artificial intelligence, and machine learning to survey biodiversity, deal with the challenges of a harsh environment, and demonstrate that these ecosystems are worth preserving.

Specifically, the winning team will survey biodiversity in at least three stories of a rainforest (emergent, canopy, understory, and forest floor) in eight hours to produce the most comprehensive biodiversity assessment and utilize this and other data to produce the greatest number of insights in 48 hours. Insights may include, but are not limited to, new ecological dependencies, biodiversity and climate connectivity, anthropological findings, or even sustainable societal interactions with the forest.

The competition includes seven months for team registration and three months for initial technical document submission. A total prize purse of $10M will be awarded throughout the lifespan of the prize, including up to $500K in bonus prizes for innovative approaches to species identification. Milestone prizes will also be awarded equally for up to 10 final teams that advance through the semi-finals.

Throughout the life cycle of the competition and following the grand prize awards ceremony, XPRIZE will work to support and scale the impact of the teams’ work and promote education around rainforest preservation.

The Rainforest XPRIZE originated from Future of Forests Impact Roadmap. The Future of Forests Impact Roadmap identified six areas for breakthroughs that could usher in a preferred future for the world’s forests, one in which forests live in harmony in an environment that balances a healthy ecosystem with humanity’s changing needs, including economic growth, social progress, and political stability.

The deadline for teams to register through the XPRIZE website is June 30, 2020. Beginning July 1, 2020 to September 23, 2020 teams can request late registration, that will be at the discretion of XPRIZE. For more information, and to register your intent to compete, visit rainforest.xprize.org.

XPRIZE

XPRIZE designs and operates multi-million-dollar, global competitions to incentivize the development of technological breakthroughs that accelerate humanity toward a better future. Active competitions include the $20 Million NRG COSIA Carbon XPRIZE, the $10 Million ANA Avatar XPRIZE and the $5 Million IBM Watson AI XPRIZE. For more information, visit xprize.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Katherine Schelbert
katherine.schelbert@xprize.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release

NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o

FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release

Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye